The Interaction Between Metformin and Acute Exercise
Status:
Completed
Trial end date:
2018-10-01
Target enrollment:
Participant gender:
Summary
Physical activity is a first line treatment for patients with type 2 diabetes (T2D), however,
the vast majority of patients with T2D do not achieve satisfying glycemic control with
physical activity alone, which is why pharmacological treatment with metformin is most often
initiated.
It is known that metformin and exercise both activates 5' adenosine monophosphate-activated
protein kinase (AMPK) in skeletal muscle and liver, and the activation of AMPK results in
many different metabolic effects, including improvements in glycemic control. Because of this
similarity in mechanism of action, an interaction between metformin and exercise is
plausible, but knowledge in the area is sparse. Thus, the aim of this study is to assess the
effects of acute physical activity with and without concomitant metformin treatment, in order
to investigate whether an interaction between the two occur.
Subjects with impaired glucose tolerance will be randomized (1:1) to metformin/placebo
treatment in a double-blinded way. Following a treatment run-in period of 17 days, two
experimental days (one with acute exercise and one without acute exercise), separated by one
week, will be performed in each subject.
This registration concerns a sub-study of another study which has previously been registrered
at ClinicalTrials.gov (Unique Protocol ID: H-17012307). The specific outcomes in this
registration have not previously been registered.